- Home
- TRVI
as 11-15-2024 4:00pm EST
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 211.4M | IPO Year: | 2019 |
| Target Price: | $9.13 | AVG Volume (30 days): | 659.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.97 - $4.00 | Next Earning Date: | 11-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Trevi Therapeutics Inc. (TRVI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| GOOD JENNIFER L | TRVI | President & CEO | Sep 6 '24 | Sell | $3.03 | 6,059 | $18,371.02 | 213,313 | |
| GOOD JENNIFER L | TRVI | President & CEO | Sep 3 '24 | Sell | $3.05 | 55,121 | $170,192.71 | 213,313 | |
| Meeker David P | TRVI | Director | Aug 27 '24 | Sell | $2.93 | 4,555 | $13,352.53 | 352,489 | |
| SCIASCIA THOMAS | TRVI | Chief Scientific Officer | Aug 19 '24 | Sell | $2.96 | 16,496 | $48,882.60 | 220,315 |
Latest Trevi Therapeutics Inc. News
TRVI Breaking Stock News: Dive into TRVI Ticker-Specific Updates for Smart Investing
Thomson Reuters StreetEvents
10 days ago
Q3 2024 Trevi Therapeutics Inc Earnings Call
GuruFocus.com
10 days ago
Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ...
PR Newswire
11 days ago
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
PR Newswire
18 days ago
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024
GuruFocus.com
25 days ago
Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc.
MT Newswires
a month ago
Trevi Therapeutics Completes Enrollment for Phase 2a Trial of Refractory Chronic Cough Treatment; Shares Rise
PR Newswire
a month ago
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
PR Newswire
a month ago
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
Compare TRVI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TRVI Trevi Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.